They Are Studying the Risks of Vision Loss from Weight Loss Medications

• Weight loss medications are associated with an increased risk of serious eye disorders.
• Studies have identified an elevated risk of NAION in patients with diabetes.
• It is essential to conduct regular monitoring of vision in patients who take these medications.

Research has shown that weight loss medications, such as Ozempic, lead to an increased risk of serious eye disorders, including vision loss. Two new studies indicate concerning conditions that may arise in individuals taking these drugs.

One of the studies, published in JAMA, analyzed data from nearly 1.5 million people and found that those with diabetes who take medications such as semaglutide or tirzepatide have an elevated risk of developing vision disorders of the optic nerve.

Particular attention is drawn to a rare but serious condition known as non-arteritic anterior ischemic optic neuropathy (NAION), which can lead to "insult to the eye." Patients typically report this problem only after experiencing vision loss in one eye. There is currently no treatment for this condition.

The studies also indicated that 35 out of 159,000 people with type 2 diabetes who took semaglutide or tirzepatide developed NAION, which translates to approximately 1 in 2,500. At the same time, another large study involving 185,000 people links weight loss medications to an increased risk of diabetic retinopathy.

Regardless of the fact that the risk of developing these conditions remains low, researchers emphasize the need for larger ongoing monitoring of patients who take these medications. They also highlight the necessity of conducting longer-term studies for a deeper understanding of the effects of these medications on the eyes.

Tags: Research